RGD Reference Report - Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease.

Authors: Broedl, UC  Schachinger, V  Lingenhel, A  Lehrke, M  Stark, R  Seibold, F  Goke, B  Kronenberg, F  Parhofer, KG  Konrad-Zerna, A 
Citation: Broedl UC, etal., Inflamm Bowel Dis. 2007 Apr;13(4):391-7.
RGD ID: 5685660
Pubmed: PMID:17206692   (View Abstract at PubMed)
DOI: DOI:10.1002/ibd.20078   (Journal Full-text)

BACKGROUND: ApoA-IV, an apolipoprotein (apo) with antioxidant, antiatherogenic, and antiinflammatory properties, was recently demonstrated to inhibit dextran sulfate sodium (DSS)-induced experimental colitis in mice. We therefore hypothesized that apoA-IV may be associated with disease activity in patients with inflammatory bowel disease (IBD). METHODS: We addressed this question by testing for associations between apoA-IV genotypes, apoA-IV plasma levels, inflammatory parameters, and clinical disease activity in 206 patients with Crohn's disease (CD), 95 subjects with ulcerative colitis (UC), and 157 healthy controls. RESULTS: In CD patients, apoA-IV plasma levels were inversely associated with C-reactive protein (CRP) (P = 0.005) and disease activity (P = 0.01) in univariate analysis. In multiple logistic regression analysis, apoA-IV levels were identified as an independent predictor of elevated CRP (odds ratio [OR] 0.956, 95% confidence interval [CI]: 0.916-0.998, P = 0.04) and active disease (OR 0.957, 95% CI: 0.918-0.998, P = 0.04). In UC patients the apoA-IV gene variant 360 His (P = 0.03) but not apoA-IV levels (P = 0.15) were associated with increased disease activity in univariate analysis. This association, however, was lost in multiple logistic regression analysis (OR 3.435, 95% CI 0.995-11.853, P = 0.05). CONCLUSIONS: To our knowledge, this is the first study to demonstrate an association of apoA-IV with disease activity in patients with CD. Further studies are needed to define the relationship of apoA-IV to IBD.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
APOA4HumanCrohn's disease severityIEP protein:decreased expression:blood plasma (human)RGD 
Apoa4RatCrohn's disease severityISOAPOA4 (Homo sapiens)protein:decreased expression:blood plasma (human)RGD 
Apoa4MouseCrohn's disease severityISOAPOA4 (Homo sapiens)protein:decreased expression:blood plasma (human)RGD 
APOA4Humanulcerative colitis severityIAGP DNA:missense mutation:cds:p.Q360H (human)RGD 
Apoa4Ratulcerative colitis severityISOAPOA4 (Homo sapiens)DNA:missense mutation:cds:p.Q360H (human)RGD 
Apoa4Mouseulcerative colitis severityISOAPOA4 (Homo sapiens)DNA:missense mutation:cds:p.Q360H (human)RGD 

Phenotype Annotations    Click to see Annotation Detail View

Manual Human Phenotype Annotations - RGD

Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
APOA4HumanBloody diarrhea severityIAGP DNA:missense mutation:cds:p.Q360HRGD 
APOA4HumanInflammation of the large intestine severityIAGP DNA:missense mutation:cds:p.Q360HRGD 
Objects Annotated

Genes (Rattus norvegicus)
Apoa4  (apolipoprotein A4)

Genes (Mus musculus)
Apoa4  (apolipoprotein A-IV)

Genes (Homo sapiens)
APOA4  (apolipoprotein A4)


Additional Information